Alembic receives FDA nod for generic Pataday

Press enter to search
Close search
Open Menu

Alembic receives FDA nod for generic Pataday

By Sandra Levy - 05/16/2019
Alembic has received the Food and Drug Administration’s clearance for olopatadine hydrochloride ophthalmic solution, 0.2%.

The product is the generic of Novartis’s Pataday ophthalmic solution 0.2%. It is indicated for the treatment of ocular itching associated with allergic conjunctivitis.

Olopatadine hydrochloride ophthalmic solution, 0.2% had a market value of $62 million for the 12 months ending December 2018, according to IQVIA data.

RELATED TOPICS